Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 153Carcinoma, Non-Small-Cell Lung 94Neoplasms 57Breast Neoplasms 50Urinary Bladder Neoplasms 47Neoplasm Metastasis 43Lung Neoplasms 41Ovarian Neoplasms 36Cholangiocarcinoma 31Lymphoma 20Sarcoma 19Gallbladder Neoplasms 19Fallopian Tube Neoplasms 19Lymphoma, Large B-Cell, Diffuse 18Biliary Tract Neoplasms 18Recurrence 15Lymphoma, Non-Hodgkin 15Adenocarcinoma 14Hodgkin Disease 13Carcinoma, Transitional Cell 13Bile Duct Neoplasms 13Carcinoma 12Colorectal Neoplasms 10Head and Neck Neoplasms 8Carcinoma, Renal Cell 8Urethral Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7Carcinoma, Ovarian Epithelial 7Adenocarcinoma of Lung 7Uterine Cervical Neoplasms 6

Interventions

adavosertib 1Paclitaxel 1Gemcitabine 1Carboplatin 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation × Gemcitabine × Clear all
NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AstraZeneca

Phase 2 Completed
95 enrolled 61 charts
Gynecologic

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡